ANCA associated vasculitis
Conditions
Interventions
intervention group:Granulocyte and monocyte adsorption
Sponsors
Peking Union Medical College Hospital
Eligibility
Sex/Gender
All
Age
18 Years to 80 Years
Inclusion criteria
Inclusion criteria: 1: newly diagnosed or relapsed microscopic polyangitis or granulomatous polyangitis, diagnosed in accordance with the 2012 Chapel Hill meeting, with positive serum MPO-ANCA or PR3-ANCA 2: eGFR=30ml/min/1.73m^2 3: proteinuria>0.5g/g Cr (or 24-hour urine protein>0.5g) with hematuria positivity = 2+
Exclusion criteria
Exclusion criteria: 1: rapidly progressive glomerulonephritis, alveolar bleeding leading to respiratory failure, multiple mononeuritis, or central nervous system involvement 2: combined with other autoimmune diseases, tumors, and severe cardiac insufficiency (NYHA III-IV level) 3: neutrophils<2 × 10 ^ 9/L 4: within 12 weeks prior to screening, treatment with cyclophosphamide, rituximab, or intravenous corticosteroids exceeding 3g or continuous oral corticosteroids of 10mg qd for more than 4 weeks 5: contraindications to primary treatment due to co infection (such as septic shock, active viral hepatitis, etc.) determined by researches
Design outcomes
Secondary
| Measure | Time frame |
|---|---|
| Proportion of patients with renal response;24-hour urine protein;Vasculitis injury index;Overall exposure to glucocorticoids; | — |
Primary
| Measure | Time frame |
|---|---|
| BVAS; | — |
Countries
China
Contacts
Public ContactHaiting Wu
Peking Union Medical College Hospital
Outcome results
None listed